Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-291 in Relapsed or Refractory Non-Hodgkin's Lymphoma
NCT06667687Phase 1Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2025
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 1, open-label trial of ABBV-291 in non-Hodgkin lymphoma (NHL) (6 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants with Adverse Events up to 74 Months, Percentage of Participants with Dose Limiting Toxicities up to 74 Months and 4 more. Started Jan 2025; status: active, not recruiting.
02
Drugs
ABBV-291
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT06667687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06667687.